OXFORD, UK: Oxford Biomedica plc (LSE:OXB) introduced the appointment of Dr Frank Mathias as Chief Executive Officer (CEO) and Board Director, efficient March 2023.
Dr Frank Mathias brings world-class innovation and contract development and manufacturing expertise to Oxford Biomedica.
Since 2016 he has served as CEO of Rentschler Biopharma SE (“Rentschler”), which he has efficiently developed right into a number one global, full-service CDMO. During the previous six years, Dr Mathias has overseen a tripling of revenues, transformed the business, elevated efficiencies and enhanced profitability even faster than revenues. At Rentschler, he additionally led the acquisition and rapid integration of a brand new site from Shire in Milford close to Boston, US, and the institution of a brand new gene therapies unit in Stevenage, UK.
During his tenure, Rentschler was additionally the primary CDMO in Europe to support the commercial manufacturing of the mRNA vaccine for BioNTech and additionally efficiently transferred the commercial manufacturing course of for Curevac’s mRNA vaccine.
Prior to Rentschler, Dr Mathias was CEO of publicly listed Medigene AG, an immuno-oncology firm specializing in the event of T-cell-based most cancers therapies. Over the course of his 30-year career, Dr Mathias has additionally served in senior roles at main global pharmaceutical companies together with Amgen, Servier and Hoechst AG. In 2019 he was awarded the title of “EY Entrepreneur of the Year” in Germany.
Dr Roch Doliveux will stay as Interim CEO of Oxford Biomedica till March 2023, at which level Dr Mathias will fully take over the role of CEO and Dr Doliveux will resume the role of Non-Executive Chair.
Commenting on the appointment, Dr Roch Doliveux, Chair and Interim CEO of Oxford Biomedica, said: “I, on behalf of the Board, am delighted to welcome Frank as CEO of Oxford Biomedica.
Frank is an excellent affected person centric chief with spectacular expertise from a top-end CDMO in addition to from innovative biopharma companies. He has a strong track record of delivering growth and driving efficiency and innovation that are core strengths required to implement our technique of becoming an innovative global viral vector leader. I know that Frank will drive our viral vector management to unleash the potential of cell and gene remedy for biopharma companies to save many lives.”
Dr Frank Mathias, incoming Chief Executive Officer, said: “Oxford Biomedica is a world-leader within the innovative development and manufacture of viral vectors for life-saving cell and gene therapies, demonstrated by the ever-expanding buyer base of now greater than 20 programmes throughout all vector types.
With momentum persevering with to construct throughout the business, I am excited by the potential for the Company. I look ahead to becoming a member of Oxford Biomedica and dealing with all of the staff, the Board and companions to execute the technique and ship the subsequent phase of growth as a world-class, innovation-led CDMO serving to to enhance the lives of patients.”